Well, perhaps not as far as known, but the general microfluidic platform they were working with was supposed to at least be capable of microfluidic capabilites

Well, perhaps not as far as known, but the general microfluidic platform they were working with was supposed to at least be capable of microfluidic capabilites (i.e. comparable to a DNA microfluidics system for DNA sequencing of the kind developed ~20 years ago). If that was working, now imagine a chip platform, a small wafer or plate containing ID sequences of the top 100 known human infectious diseases, in that situation possibly you could get a one-shot test using just 200 ul of blood, distributing 2 ul to each (non-quantitative, +/- test). Then you'd test it, see what your limit of detection is and so on. If this was automated and reliable, it'd be very valuable for many different purposes (you could also have specialized chips for all known respiratory viral types, all common water-borne pathogens, all known STDs, etc) Of course, that'd be a much smaller market, maybe only a fraction of the value of the whole quantitative blood component level testing industry.